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Abstract
The PSA-Cre;Pten-loxP/loxP mouse prostate cancer model displays clearly defined stages of hyperplasia and cancer. Here, the
initial stages of hyperplasia development are studied. Immunohistochemical staining showed that accumulated pAkt
+
hyperplastic cells overexpress luminal epithelial cell marker CK8, and progenitor cell markers CK19 and Sca-1, but not basal
epithelial cell markers. By expression profiling we identified novel hyperplastic cell markers, including Tacstd2 and Clu.
Further we showed that at young age prostates of targeted Pten knockout mice contained in the luminal epithelial cell layer
single pAkt
+ cells, which overexpressed CK8, Sca-1, Tacstd2 and Clu; basal epithelial cells were always pAkt
2. Importantly, in
the luminal epithelial cell layer of normal prostates we detected rare Clu
+Tacstd2
+Sca-1
+ progenitor cells. These novel cells
are candidate tumor initiating cells in Pten knockout mice. Remarkably, all luminal epithelial cells in the proximal region of
normal prostates were Clu
+Tacstd2
+Sca-1
+. However, in PSA-Cre;Pten-loxP/loxP mice, the proximal prostate does not contain
hyperplastic foci. Small hyperplastic foci in prostates of PSA-Cre;Pten-loxP/+ mice found at old age, showed complete Pten
inactivation and a progenitor marker profile. Finally, we present a novel model of prostate development and renewal,
including lineage-specific luminal epithelial progenitor cells. It is proposed that Pten deficiency induces a shift in the balance
of differentiation to proliferation in these cells.
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Introduction
Prostate cancer is the most common tumor in men in countries
with a western lifestyle, and a major cause of cancer-related
mortality [1]. Complete PTEN inactivation is found in ,20% of
primary prostate tumors and in up to 60% of prostate cancer
metastases [2]. Inactivation of one PTEN allele is even more
common. High frequency of PTEN inactivation is found also in
endometrium cancer and in glioblastoma [3]. Germ line mutations
of PTEN are the cause of Cowden disease and Bannayan-Zonana
syndrome, which are characterized by hamartomas and predis-
position to breast and thyroid tumors [2,3].
PTEN counteracts phosphoinositide-3-kinase (PI3K) signaling
by balancing phosphatidylinositol (4,5)-phosphate (PIP2) and
phosphatidylinositol (3,4,5)-phosphate (PIP3) levels in the cell [2–
4]. PIP3 accumulation leads to phosphorylation of downstream
targets, including AKT. As a consequence the activities of further
downstream effectors are modulated and cell biological functions,
including proliferation, apoptosis, cell size, polarity, metabolism,
adhesion, migration and angiogenesis are changed [3–6]. Nuclear
PTEN might play a role in maintaining genomic stability [7].
Moreover, it has recently been described that PTEN can control
stem cell self-renewal [6,8,9].
Complete Pten inactivation in mice is embryonic lethal. Pten+/2
mice are viable but develop several hyperplastic and dysplastic
lesions in different organs [10,11]. Conditional Pten knockout
mouse models confirmed that Pten inactivation plays an important
role in cancer development and tumor progression. Mice with
prostate-specific Pten inactivation develop hyperplasia, mPIN and
ultimately prostate cancer [12–15].
As first identified for hematopoietic cells, it is now generally
accepted that all tissues contain rare tissue-specific stem cells that
are capable of self-renewal and of differentiation through
asymmetrical cell division [16,17]. These cells are not only
essential for organogenesis during development, but also for tissue
renewal in the adult species. As clearly shown in different types of
leukemia, tumors might develop by modification of hematopoietic
stem cells or, alternatively, from multipotent or lineage-specific
progenitor cells that have acquired stem cell-like characteristics
[18]. Although less clear, the same mechanism has been proposed
for the development of solid tumors, including prostate cancer.
According to the stem cell model, each tumor contains a small
number of cells with properties related to normal stem cells, that
are essential for tumor maintenance [16,19–21]. Complementary
to the tumor stem cell theory, the clonal evolution model proposes
that tumors can develop by expansion of dominant clones [22–24].
Study of tumor development in mouse prostate cancer models
can be instrumental in understanding human prostate cancer. In
the normal human and mouse prostate, stem cells and multipotent
progenitor cells, or transit-amplifying cells, are proposed to be
present in the basal epithelial cell layer [21,25–27]. In addition, in
mice, the proximal region of the prostate has been indicated as a
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knowledge of initial steps in tumor development in mouse models
of prostate cancer is limited. In the Probasin(PB)-Cre induced Pten
knockout model, Pten inactivation in a p63
+ stem/progenitor cell
population in the basal epithelial cell layer has been postulated
[31]. In a prostate-specific Trp53/Rb knockout model, luminal/
neuroendocrine progenitor cells in the proximal prostate have
been indicated as potential tumor initiating cells [32].
In the present study we investigated early steps in prostate tumor
development in a different targeted Pten inactivation model, based
on PSA-Cre expression. Previously, we described that in this model
clearly defined stages of prostate hyperplasia and cancer can be
discriminated [13]. Here we showed that hyperplastic cells in Pten
knockout mice have a phenotype of luminal epithelial progenitor
cells, including overexpression of CK8, CK19 and Sca-1. By
expression profiling novel hyperplastic cell markers were identified.
The first hyperplastic pAkt
+ cells inprostates of young Pten knockout
mice were found in the luminal epithelial cell layer. Importantly, we
also identified at low frequency novel lineage-specific progenitor
cells in the luminal epithelial cell layer of normal prostates. These
cells might represent earlier postulated luminal intermediate/
transit-amplifying cells [33,34]. Our findings indicate that Pten
inactivation in this mouse model leads to accumulation of the novel
identified luminal epithelial progenitor cells by a drastic change of
the differentiation/proliferation balance of these cells. Although all
cells in the luminal epithelial cell layer in the proximal prostate
showed expression of the novel lineage-specific markers, hyperplas-
tic foci did not develop from this region of the prostate.
Results
Hyperplastic cells in prostates of PSA-Cre;Pten-loxP/loxP
mice have a phenotype of luminal epithelial cells and
express epithelial progenitor cell markers
Previously, we described prostate cancer development in PSA-
Cre;Pten-loxP/loxP mice [13]. In prostates of 4–5 months (4–5m)
old PSA-Cre;Pten-loxP/loxP mice hyperplastic epithelial cells
overexpress Phospho-Akt (pAkt) and the luminal epithelial
markers Cytokeratins 8/18 (CK8/18). Hyperplastic cells were
negative for the basal epithelial markers Cytokeratins 5/14 (CK5/
14). The androgen receptor (AR) was expressed at equal levels in
normal and hyperplastic prostates [13].
In the present study we characterized by QPCR and immuno-
histochemistry hyperplastic prostate cells of PSA-Cre;Pten-loxP/loxP
mice. First, the expression of additional progenitor, basal and
luminal epithelial cell markers was analyzed at 2m and at 4–5m. At
these ages prostates of PSA-Cre;Pten-loxP/loxP mice are for ,70%
and .90% hyperplastic, respectively (Figure S1A). Expression of
Probasin and Nkx3.1, markers of differentiated luminal cells, was
much lower in hyperplastic prostates, but CK8 was higher expressed
in these tissues. Low expression of the basal epithelial cell markers
CK5 and p63 was detected. Interestingly, expression of the epithelial
progenitor cell marker CK19 [35,36] was high in hyperplastic
prostates. Nkx3.1, CK8, CK19 and p63 mRNA expression data were
confirmed by immunohistochemistry on normal and hyperplastic
prostates (4–5m) (Figure S1B–S1I). Nuclear Nkx3.1 staining was
seen in luminal epithelial cells of normal prostates, but nuclei of
hyperplastic cells were hardly positive (Figure S1B–S1C). A faint
CK8 staining was observed at the apical side of luminal epithelial
cells in normal prostates, whereas in hyperplastic prostates of PSA-
Cre;Pten-loxP/loxP mice CK8 was overexpressed (Figure S1D–S1E).
Importantly, CK19 was clearly higher expressed in hyperplastic
cells than in normal prostate epithelial cells (Fig. S1F–S1G).
Hyperplastic cells were negative for the basal epithelial cell marker
p63, but an apparent normal p63
+ basal epithelial cell layer was
present below a multilayer of hyperplastic cells (Figure S1H–S1I).
From these data we conclude that Pten inactivation in prostates of
PSA-Cre;Pten-loxP/loxP mice results in the accumulation of hyper-
plastic cells with luminal progenitor cell characteristics (Nkx3.1
+/2
CK8
+CK19
+p63
2).
Expression profiling identifies novel genes with high
expression in hyperplastic prostate epithelium
Expression profiling was performed to identify novel genes
differentially expressed in hyperplastic prostates of PSA-Cre;Pten-
loxP/loxP mice (4–5m). Principal Component Analysis (PCA) and
unsupervised hierarchical clustering (Figure 1A and 1B) of the
cDNA array data showed a clear differential gene expression
profile between hyperplastic prostates and normal prostates.
To identify genes preferentially expressed in hyperplastic prostate
cells, differences in mean expression levels were calculated. The
mouse progenitor/stem cell marker Sca-1 was one of the top twenty
genes with the highest expression in hyperplastic prostates
(Figure 1C); CK19 was in the top fifty differentially expressed genes
(data notshown).Genesthat showedhigh expression inhyperplastic
prostates by calculation of differences in mean expression level
(Figure 1C),like Expi, Wfdc2, Tacstd2(Trop2),Clu, Ppp1r1b, Sca-1 and
CK19, were also found overexpressed by Significance Analysis of
Microarray (SAM) (Figure 1D). Full names of the top twenty
overexpressed genes are listed in Table S1. A more extensive list of
all significantly upregulated or downregulated genes identified by
SAM analysis is provided in Table S2. Note that CK19 is in the top
twenty of upregulated genes.
The expression profiles of the five genes with the highest
overexpression in hyperplastic prostates of targeted Pten knockout
mice, Expi, Wfdc2, Tacstd2, Clu and Ppp1r1b (Figure 1C), and of Sca-
1, were verified by QPCR in prostates of Pten knockout mice and
in normal prostates at 2m and at 4–5m (Figure 1E). QPCR
showed that the expression of Expi and Tacstd2 in PSA-Cre;Pten-
loxP/loxP mice was already high at 2m; Clu and Sca-1 showed a
gradually increasing expression level. However, for Wfdc2 and
Ppp1r1b the sharpest raise in expression was observed in
completely hyperplastic prostates (4–5m).
Next, expression of markers for which appropriate antibodies
were available, Tacstd2, Clu, Ppp1r1b and Sca-1, was studied by
immunohistochemistry on normal and hyperplastic prostates
(Figure 1F–1M). Tacstd2 immunohistochemistry showed mem-
brane staining in hyperplastic tissues, in agreement with its known
location as a transmembrane protein [37]. Clu was mainly present
in the cytoplasm of hyperplastic cells. As predicted from the
QPCR data, the expression pattern of Ppp1r1b in hyperplastic
cells was more heterogeneous. In agreement with the CK19
staining (Figure S1), Sca-1 staining indicated that hyperplastic cells
have a progenitor cell phenotype.
Genes with lower expression in hyperplastic prostates of PSA-
Cre;Pten-loxP/loxP mice were also identified both by calculation of
the difference in mean expression level and by SAM (Figure 1C
and 1D). The expression profiles of genes with the lowest
expression in hyperplastic prostates, Hs3st3b1, Ccdc16, Mcoln2,
C1r and Mt1 (Figure 1C), were confirmed by QPCR (Figure S2).
Expression of all genes was already low in hyperplastic prostates at
2m in PSA-Cre;Pten-loxP/loxP mice.
Initial pAkt
+ hyperplastic cells in the luminal epithelial
cell layer in prostates of PSA-Cre;Pten-loxP/loxP mice
express Clu, Tacstd2 and Sca-1
To collect information of candidate tumor initiating cells, we
examined in detail the early development of hyperplasia in prostates
The Pten Prostate Cancer Model
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Prostates of wild type mice at 4–5w were half the size of those of
adult mice (2m and 4–5m) (Figure 2A). In contrast to prostate
weights of older mice (2m and 4–5m), prostate weights of young
PSA-Cre;Pten-loxP/loxP mice (4–5w) were not different from control
littermates (Figure 2A). At 4–5m the prostate weights of PSA-
Cre;Pten-loxP/loxP mice were ,3-fold higher than those of controls,
caused by the increased number and size of hyperplastic cells.
Phospho-Akt expression was used as marker of Pten inactivation to
visualize the first Pten negative cells. At 4–5w, scattered throughout
Figure 1. Identification of new hyperplastic cell markers in prostates of PSA-Cre;Pten-loxP/loxP mice. (A) Principal component analysis
(PCA) of gene expression in normal prostates (blue circles) and hyperplastic prostates of PSA-Cre;Pten-loxP/loxP mice (red circles) at 4–5m. (B)
Unsupervised hierarchical clustering of the gene expression profiles of five normal prostates (NP) and five hyperplastic prostates (HP). Green indicates
lower gene expression and red indicates higher expression. (C) The twenty genes with the largest differential expression in HP as compared to NP as
determined by calculation of the difference in mean expression level. (D) Significance Analysis of Microarrays (SAM) of the same samples as shown in
C. Note that by SAM analysis essentially identical genes were identified as by calculation of the difference in mean expression level. (E) QPCR analysis
of the five genes with the highest expression in HP as compared to NP and of Sca-1. Each subgroup was composed of five prostate samples. The
expression levels in hyperplastic prostates of 2m and 4–5m old mice and in prostates of control littermates are shown as average expression level +/2
SE relative to Hprt expression. (F–M) Immunohistochemical analysis of newhyperplastic cell markers in NP andHP of PSA-Cre;Pten-loxP/loxPmice (4–5m).
(F) Tacstd2 NP, (G) Tacstd2 HP, (H) Clu NP, (I) Clu HP, (J) Ppp1r1b NP, (K) Ppp1r1b HP, (L) Sca-1 NP and (M) Sca-1 HP.
doi:10.1371/journal.pone.0005662.g001
The Pten Prostate Cancer Model
PLoS ONE | www.plosone.org 3 May 2009 | Volume 4 | Issue 5 | e5662all prostate lobes, single pAkt
+ hyperplastic cells and small pAkt
+ foci
were detected (Figure 2B). Importantly, all pAkt
+ cells were
exclusively present in the luminal epithelial cell layer and not in the
basal epithelial cell layer. At 2m and at 4–5m ,70% and almost
100% of the luminal epithelial cells showed pAkt membrane staining,
respectively (Figure 2C and 2D). Basal epithelial cells remained pAkt
negative. Sca-1 and the new hyperplastic cell markers Clu and
Tacstd2werealsoexpressedintheinitialhyperplasticfoci(Figure2E),
but Ppp1r1b expression could not yet be detected in hyperplastic cells
at 4–5w (data not shown).
To allow accurate characterization of initial hyperplastic pAkt
+
cells, immunofluorescent double staining was carried out
(Figure 2F–2I). Importantly, all pAkt
+ cells showed expression of
Clu and Tacstd2. Moreover, all pAkt
+ cells overexpressed CK8
and were negative for the basal epithelial cell marker p63. This
finding strongly suggests that the first pAkt
+ cells, which were
exclusively observed in the luminal epithelial layer, are identical to
the majority of accumulating hyperplastic cells with an epithelial
progenitor cell phenotype at 4–5m.
PSA-Cre;Pten-loxP/+ mice develop hyperplastic foci with
the same marker profile as hyperplastic foci in prostates
of PSA-Cre;Pten-loxP/loxP mice
Previously, we reported that heterozygous PSA-Cre;Pten-loxP/+
mice do not develop prostate tumors, but that they can develop
hyperplastic foci at older age [13]. The availability of novel
hyperplastic cell markers allowed a more accurate study of
hyperplasia development in these mice. Clu staining of prostates of
PSA-Cre;Pten-loxP/+ mice showed that already at 4–5m a few small
hyperplastic foci could be detected (Figure S3). At 7–8m the
number of hyperplastic foci was still very low, but a clear increase
of hyperplastic foci was detected in older mice (.11m). Clu
+
hyperplastic foci were not observed in prostates of control
littermates (data not shown).
Interestingly, like in prostates of young PSA-Cre;Pten-loxP/loxP
mice hyperplastic Clu
+ foci of PSA-Cre;Pten-loxP/+ mice (Figure 3A)
showed pAkt overexpression (Figure 3B). In line with this
observation Pten staining was negative in these foci (data not
shown), indicating that the second Pten allele was inactivated in the
pAkt
+ hyperplastic cells. Hyperplastic cells in PSA-Cre;Pten-loxP/+
mice were also Tacstd2 and Sca-1 positive (Figure 3C and 3D). So,
hyperplastic cells in prostates of PSA-Cre;Pten-loxP/+ mice had an
identical expression profile as hyperplastic foci in young PSA-
Cre;Pten-loxP/loxP mice.
Single Clu
+Tacstd2
+Sca-1
+ epithelial progenitor cells are
present in the luminal epithelial cell layer of normal
prostates
Next, we investigated whether hyperplastic cell markers were
expressed in normal prostates at different ages. Interestingly, at 4–
Figure 2. Single pAkt+ luminal epithelial cells in prostates of young PSA-Cre;Pten-loxP/loxP mice (4–5w) are Clu
+Tacstd2
+Sca-1
+. (A)
Prostate weights (average +/2 SE) of wild type mice and PSA-Cre;Pten-loxP/loxP mice at 4–5w, 2m and 4–5m. (B) pAkt staining of hyperplastic foci/
cells in the luminal epithelial cell layer of a prostate of a 4–5w old PSA-Cre;Pten-loxP/loxP mouse. Magnifications of three indicated regions are shown
in B1, B2 and B3. Arrow heads in B1 and B2 indicate single pAkt
+ cells. Phospho-Akt staining of prostates of 2m (C) and 4–5m (D) old PSA-Cre;Pten-
loxP/loxP mice shows that respectively ,70% and 100% of the luminal epithelial cells were pAkt
+. (E) Consecutive slides of a prostate of a 4–5w old
PSA-Cre;Pten-loxP/loxP mouse stained for Clu, Tacstd2 and Sca-1 shows coexpression of these markers in a small hyperplastic focus.
Immunofluorescent double stainings confirmed co-localization of (F) Tacstd2 and pAkt, (G) Clu and pAkt and (I) CK8 and pAkt. (H) pAkt
+ cells
were not observed in the p63
+ basal epithelial cell layer.
doi:10.1371/journal.pone.0005662.g002
The Pten Prostate Cancer Model
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+Tacstd2
+Sca-1
+ cells were detected in the luminal
epithelial cell layer of normal prostates (Figure 4A–4C). Some
basal epithelial cells stained positive for Tacstd2 and Sca-1,
however, Clu
+ cells were never observed in the basal epithelial
layer. The presence of Clu
+Tacstd2
+Sca-1
+ cells in the luminal
epithelial cell layer of normal mouse prostates suggests that these
cells are previously not yet identified lineage-specific progenitor
cells of the luminal epithelial cells. It is tempting to speculate that
in Pten knockout mice hyperplastic prostate cells with similar
characteristics as these progenitor cells originate from these cells.
This hypothesis is in line with the observation that pAkt
+
hyperplastic cells were exclusively found in the luminal epithelial
cell layer (Figure 2B, 2H, and 2I).
To estimate the frequency of Clu
+Tacstd2
+Sca-1
+ epithelial
progenitor cells at different ages, prostates from developing (4–5w)
and from adult (4–5m) mice were stained for Clu expression. At 4–
5w 1/250, and at 4–5m 1/25.000 luminal epithelial cells were
Clu
+, respectively (Figure 4A and 4D), indicating that in
developing prostates the number of lineage-specific progenitor
cells is much higher than in fully mature prostates. The presence of
Clu
+Tacstd2
+Sca-1
+ luminal progenitor cells in normal adult
prostates makes these cells candidates from which hyperplastic foci
develop in PSA-Cre;Pten-loxP/+ mice, due to inactivation of the
second Pten allele.
Clu
+Tacstd2
+ luminal epithelial progenitor cells in young
normal prostates (4–5w) were further characterized by co-
localization studies. pAkt overexpression in Clu
+Tacstd2
+ cells in
the luminal epithelial cell layer of normal prostates was never
observed (Figure 4E–4F). However, like hyperplastic cells in PSA-
Cre;Pten-loxP/loxP mice, Clu
+Tacstd2
+ cells in the luminal
epithelial cell layer of normal prostates overexpressed CK8
(Figure 4G–4H). Clu
+ cells were exclusively found in the luminal
epithelial cell layer, whereas Tacstd2
+ cells were present in both
the luminal and the basal epithelial cell layer (Figure 4G–4J, and
Figure S4). Recently, high expression of Tacstd2 has been
identified in basal epithelial cells of the proximal prostate, but
not in basal epithelial cells in the more distal prostate [38].
Hyperplastic foci do not develop from epithelial cells in
the proximal prostate
The proximal region of the mouse prostate has been proposed
as a stem/progenitor cell niche [28–30]. A schematic view of the
proximal and distal parts of a mouse prostate lobe is shown in
Figure 5A. We studied the properties of the epithelial cells in the
proximal prostate in more detail in PSA-Cre;Pten-loxP/loxP mice
and in normal littermates.
As visualized in longitudinal sections of normal prostate lobes,
luminal epithelial cells in the proximal prostate are more compact
with less cytoplasm than luminal cells in distal parts of the prostate
(Figure 5B). Like in the distal prostate, in the proximal prostate a
p63
+ basal epithelial cell layer was present below the luminal
epithelial cells (Figure 5C). Interestingly, all luminal epithelial cells
in the proximal prostate overexpressed CK8 (Figure 5D), like
observed in rare lineage-specific luminal progenitor cells in the
distal prostate and in hyperplastic cells in PSA-Cre;Pten-loxP/loxP
mice. Sca-1 was also high expressed in proximal cells (Figure 5E),
confirming that luminal epithelial cells in the proximal prostate
have a luminal progenitor phenotype. As indicated by the
interrupted line (Figure 5C–5E), there is an abrupt transition
from epithelial cells with proximal characteristics to cells with
properties of more distal luminal epithelial cells.
Next, expression profiling of proximal and distal regions of
normal adult prostates was performed (Figure 6A). Strikingly,
Figure 3. Hyperplastic cells in prostates of PSA-Cre;Pten-loxP/+ mice and PSA-Cre;Pten-loxP/loxP mice express identical markers.
Consecutive sections of a hyperplastic focus in the prostate of a PSA-Cre;Pten-loxP/+ mouse were stained for (B) pAkt and the hyperplastic cell markers
(A) Clu, (C) Tacstd2 and (D) Sca-1 by immunohistochemistry.
doi:10.1371/journal.pone.0005662.g003
The Pten Prostate Cancer Model
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highest expression in the proximal prostate. Expression array data
were confirmed by QPCR (Figure 6B). As described above, these
markers were also overexpressed in accumulated hyperplastic
prostate cells of PSA-Cre;Pten-loxP/loxP mice (Figure 1) and in rare
luminal progenitor cells in the distal prostate (Figure 4). Immu-
nohistochemistry showed high Clu, Tacstd2 and Ppp1r1b
expression in the luminal epithelial cells of the proximal prostate
(Figure 6C–6E). The cDNA array data confirmed high expression
of the luminal progenitor cell markers CK8 and Sca-1 in the
proximal prostate (data not shown). In conclusion, a correlation
was detected between the marker profile in hyperplastic prostates
of PSA-Cre;Pten-loxP/loxP mice, rare lineage-specific progenitor
cells in the distal prostate and the proximal luminal epithelial cells.
We investigated in PSA-Cre;Pten-loxP/loxP mice (4–5m) whether
hyperplastic foci developed from luminal epithelial cells in the
proximal prostate. Longitudinal sections of prostates showed that,
although the distal prostate was completely hyperplastic, the
epithelium in the proximal prostate was unaffected (Figure 6F–6I).
Immunohistochemistry showed that, in contrast to the distal
prostate, pAkt was not overexpressed in the proximal prostate
(Figure 6F), indicating that Pten is not inactivated in this region of
the prostate.
Further, we determined the marker profile of epithelial cells in
urethral epithelium adjacent to the proximal prostate. In the
superficial differentiated layer of the urothelium, the umbrella
cells, high CK8 expression was observed. The highest expression
of p63, Clu, Tacstd2, and Sca-1 was found in the intermediate/
basal epithelial cell layers (Figure S5). The urethra data extend the
prostate expression data indicating that Clu, Tacstd2 and Sca-1
show high expression in less differentiated epithelium.
Discussion
In this study we defined the early stages of hyperplasia
development in the PSA-Cre;Pten-loxP/loxP mouse prostate cancer
Figure 4. Single Clu
+Tacstd2
+Sca-1
+ cells are present in the luminal epithelial cell layer of the normal prostate. (A) Clu staining of a
normal prostate of a 4–5w old mouse. Scattered throughout the prostate lobe, single Clu
+ cells in the luminal epithelial cell layer were observed. An
overview of a whole prostate lobe and higher magnifications of three indicated regions are shown. Arrows indicate positive cells. (B) Tacstd2
+ and (C)
Sca-1
+ cells in the luminal epithelial cell layer of the developing prostate (4–5w). (D) Clu staining of an adult normal prostate (4–5m) showed rare Clu
+
cells in the luminal epithelial cell layer. (D1) Higher magnification of the indicated region in (D). (E–J) Immunofluorescent double staining of Clu
+ and
Tacstd2
+ cells in the luminal epithelial cell layer of the normal prostate. In normal prostates Clu
+ and Tacstd2
+ cells were negative for pAkt (E,F),
overexpressed CK8 (G,H) and did not express p63 (I,J).
doi:10.1371/journal.pone.0005662.g004
The Pten Prostate Cancer Model
PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5662model. Important aspects of early hyperplasia development and
normal prostate development were sequentially addressed. We
showed that: (i) Accumulating hyperplastic pAkt
+ cells in prostates
of PSA-Cre;Pten-loxP/loxP mice have a luminal epithelial cell
phenotype with expression of known and novel identified markers
of epithelial progenitor cells. (ii) The earliest single pAkt
+ (Pten
2)
hyperplastic cells in the prostates of young targeted Pten knockout
mice are exclusively present in the luminal epithelial cell layer. (iii)
At low frequency, in the normal prostate, similar cells, but without
pAkt overexpression, could be identified. (iv) Our data indicate
further that Pten inactivation inhibits differentiation of luminal
epithelial progenitor cells to mature cells. (v) We observed that the
luminal epithelial cell layer of the proximal prostate is composed of
cells that express the same markers as rare progenitor cells in more
distal prostate regions. However, hyperplastic foci did not develop
from the proximal prostate. (vi) Finally, we showed that at older
age PSA-Cre;Pten-loxP/+ mice developed in the prostate pAkt
+
hyperplastic foci with an identical marker profile as in young PSA-
Cre;Pten-loxP/loxP mice.
Our data accumulate into a hierarchical model of prostate
renewal in which we define novel Clu
+Tacstd2
+Sca-1
+ lineage-
specific progenitor cells in the luminal epithelial layer of the
normal prostate (Figure 7). We presume that, according to
previous findings, prostate stem/multi-potent progenitor cells are
situated in the basal epithelial cell layer [21,25–27,34,39]. This cell
layer might also contain lineage-specific progenitor cells of the
basal epithelial cells. CK19 and Sca-1 positive cells are present
both in the luminal and basal epithelial cell layer of the prostate
[35,36], but the expression of other epithelial cell markers differs in
these cell populations. The CK19
+CK8
+Clu
+Tacstd2
+Sca1
+
luminal epithelial progenitor cells as identified in this study are
strong candidate tumor initiating cells in the Pten knockout
prostate cancer model (Figure 7). This contrasts the opinion that
prostate tumors should be derived from tissue stem cells or
multipotent progenitor cells in the basal epithelial cell layer.
It is well-established that complete Pten inactivation in Pten2/2
mice is embryonic lethal. These mice die at embryonic days 7–9,
indicative for an important role of Pten in development. Pten+/2
mice are viable, but develop during aging several tumor types,
mostly T-cell lymphomas [10,11]. During recent years, several
mouse prostate cancer models based on Pten inactivation have
been generated. In essentially all models, mice with prostate-
specific Pten inactivation showed development of hyperplasia,
mPIN lesions and ultimately prostate cancer [12–15]. Prostate
hyperplasia in Pten knockout mice is characterized by cell
enlargement, in line with the properties of Pten as regulator of
cell size and protein synthesis [6,40]. Accumulation of enlarged
hyperplastic cells is unique for Pten inactivation in the prostate, and
has not been seen in mouse prostate cancer models based on
different genetic alterations [41–46].
Most studies in targeted Pten knockout prostate cancer models
use mice with Pten inactivation by PB-Cre [14,15,31]. These mice
develop hyperplasia early during prostate development, rapidly
progressing to invasive tumors, accompanied by metastases
[15,31]. The slow model studied here, using Cre driven by the
PSA promoter, induces clearly separate stages of hyperplasia and
cancer progression [13]. Although the PSA promoter used is of
human origin, it drives very specific transgene expression in the
luminal epithelial cell layer of the mouse prostate [47].
Although hyperplastic Pten negative cells express AR [13], they
are blocked in differentiation to mature cells, as deduced from the
low expression of Nkx3.1 and Probasin (Figure S1). So far, a role of
Pten in differentiation of prostate luminal epithelial cells was
unknown. Available data on the effect of Pten on differentiation in
other systems is incomplete and conflicting. Pten deficiency was
shown to stimulate neural stem cell proliferation without affecting
differentiation [48,49]. Mice with Pten inactivation in osteoblasts
showed enhanced differentiation [50]. Based on the stimulation of
cell proliferation by PTEN deficiency in many systems, it might be
assumed that Pten inactivation stimulates proliferation of the
Figure 5. All luminal epithelial cells in the proximal prostate express luminal epithelial progenitor cell markers. (A) Schematic picture
of a mouse prostate lobe indicating the urethra, the proximal and the distal prostate region. (B) Heamatoxylin eosin staining of a longitudinal
positioned mouse prostate lobe. Magnifications of the distal (B1) and the proximal (B2) prostate, as indicated in B, showed a difference in
morphology of the luminal epithelial cells in the proximal and the distal prostate. (C–E) Immunohistochemical analysis of luminal epithelial cells in the
proximal region of a normal mouse prostate. (C) p63; (D) CK8 and (E) Sca-1 staining. Dashed lines indicate the abrupt transition of epithelium of the
proximal to the distal prostate.
doi:10.1371/journal.pone.0005662.g005
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might also be an intrinsic property of these cells [13].
None of the genes with clear differential expression in
hyperplastic prostates compared to normal prostates (Figure 1
and Figure S1) could be directly correlated to Pten signaling.
Expression of known FOXO targets, one of the best studied
downstream effectors of pAkt, was not clearly detected amongst
the differentially expressed genes in hyperplastic prostates [51]. So,
the differentially expressed genes are markers of the cell
population enriched in hyperplastic prostates, indirectly induced
by Pten inactivation.
The gene expression profile of the hyperplastic prostate
presented in this study showed overlap with the gene expression
profiles of prostate tumors of PB-Cre;Pten-loxP/loxP mice [15] and
tumors from PSA-Cre;Pten-loxP/loxP mice (H. Korsten, unpub-
lished). Out of the 50 genes with the highest expression in prostate
tumors of PB-Cre;Pten knockout mice, 22 genes were present on our
expression arrays. Almost all these genes showed higher expression
in hyperplastic prostates of PSA-Cre;Pten-loxP/loxP mice. Five
genes, Expi, Clu, Anxa3, Tacstd2 and Cbr2, were among the top
20 genes with the highest expression in hyperplastic prostates
(Figure 1C). Overexpression of genes in both hyperplasia and
tumor indicates that altered expression of these specific genes is
not sufficient for development of invasive tumors. A limited
number of genes, including Col3a1, seems preferentially overex-
pressed in tumors [15]. These genes are candidate prostate tumor
markers.
An important issue addressed in this study concerns the
properties of the first altered cells. We scanned thoroughly
prostates at 4–5w for cells overexpressing pAkt, as very sensitive
marker for Pten inactivation. We never observed pAkt
+ cells in the
basal epithelial cell layer, although in the luminal epithelial cell
layer single pAkt
+ cells and small foci of pAkt
+ cells were easily
detected. High expression of hyperplasia markers Clu, Tacstd2
and Sca-1 was also found in the first hyperplastic cells in the
luminal epithelial cell layer at 4–5w. Importantly, the Clu
+-
Tacstd2
+Sca-1
+ cells, which also overexpress CK8, are at low
frequency detectable in the luminal epithelial cell layer of normal
prostates. Hence, we propose that these lineage-specific progenitor
cells, as first identified in this study, are the target cells for Pten
inactivation in the prostate cancer model (Figure 7). This would be
in line with the properties of the PSA promoter/enhancer used to
drive Cre expression, which is active in luminal epithelial cells of
the mouse prostate [47] and in the more differentiated luminal
epithelial cells in the human prostate. Our data indicate expansion
of a rather homogeneous hyperplastic progenitor cell population
induced by Pten inactivation as the first step in tumorigenesis.
Follow-up studies, including orthotopic transplantation of hyper-
plastic cells in syngenic mice with a homogeneous genetic
background should reveal further information on the mechanism
of tumor development.
Figure 6. Hyperplastic prostates of PSA-Cre;Pten-loxP/loxP mice
and luminal epithelial cells in the proximal prostate overex-
press identical genes. (A) Expression profiling of the proximal and
distal prostate region of a normal mouse prostate (4–5m) shows that
genes high expressed in hyperplastic prostates of PSA-Cre;Pten-loxP/loxP
mice are among the ten genes with the highest expression in two
proximal prostates as compared to two distal prostates. (B) QPCR
analysis of hyperplasia markers with high expression in the proximal
prostate. (C–E) Immunohistochemical analysis confirms high expression
of hyperplastic cell markers in the luminal epithelial cell layer of the
proximal region of the normal prostate. (C) Clu staining of a normal
prostate lobe, (C1) magnification of the transition of the proximal to the
distal region as indicated in C. Staining for (D) Ppp1r1b and (E) Tacstd2.
Hyperplasia development did not occur in the proximal prostate of PSA-
Cre;Pten-loxP/loxP mice (4–5m). Proximal luminal epithelial cells of the
hyperplastic prostates were negative for pAkt (F, magnification of
transition proximal/distal prostate in F1), although these cells overex-
pressed (G, G1) Clu, (H) Ppp1r1b and (I) Tacstd2.
doi:10.1371/journal.pone.0005662.g006
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+Tacstd2
+Sca-1
+
progenitor cells in the luminal epithelial cell layer share
characteristics with previously postulated luminal intermediate/
transit-amplifying cells [33–36]. Multipotent transit-amplifying
cells co-express basal epithelial cell and luminal epithelial cell
markers, whereas the more differentiated intermediate/transit-
amplifying cells in the luminal epithelial cell layer are negative for
basal epithelial cell markers, but express CK8 and CK19 [35,36].
It was proposed that the cell of origin for prostate cancer is a stem
cell or transit-amplifying cell in the basal epithelial cell layer
[33,34]. Here, we show that progenitor cells with characteristics of
intermediate/transient-amplifying cells in the luminal epithelial
cell layer can function as tumor initiating cells in prostate cancer
(Figure 7). Obviously, this does not exclude the possibility that
stem cells and multipotent progenitor cells can have similar
properties. This might depend on the properties of the gene that is
activated or inactivated, and on the (promoter) system used to
accomplish targeted gene activation or inactivation.
Our findings are substantially different from the PB-Cre;Pten
knockout mouse model [31]. In these mice it was proposed that
Pten inactivation in stem/multipotent progenitor cells in the basal
epithelial cell layer is the initial event in prostate tumor
development. In contrast to the PSA-Cre;Pten knockout mouse
model, in this model proliferation of p63
+ basal epithelial cells was
observed. Hence, the modified PB promoter seems active in
multipotent progenitor cells, whereas the PSA promoter/enhancer
is active in lineage-specific luminal progenitor cells. Although
comparison with human prostate cancer has its limitations, it
should be noted that human prostate tumors do not show an
increase in p63
+ cells. In fact, negative staining for p63 is
considered as indication of prostate cancer [52].
Although preliminary data are available [30,53–55], further
identification and characterization of candidate prostate stem cells
and different types of progenitor cells is essential for unraveling
prostate development and tumor initiation in mouse models. In
normal mouse prostates a Sca-1
+Integrina6
+ (CD49f) enriched cell
population in the basal epithelial cell layer was reported to possess
stem cell characteristics [38,55]. Preliminary QPCR analysis of
hyperplastic prostates of PSA-Cre;Pten-loxP/loxP mice indicated that
integrina6( CD49f) mRNA expression was not substantially altered
(H. Korsten, unpublished). However, we did find higher
expression in hyperplastic prostates of integrina2 (CD49b) (H.
Korsten, unpublished), also observed to be overexpressed in a cell
population enriched for stem/progenitor cells in the human
prostate [56,57]. Recently, another mouse prostate stem cell
population was defined by a Sca-1
+CD133
+CD44
+CD117
+
Figure 7. Model for hyperplasia development in PSA-Cre;Pten-loxP/loxP mice. The model shows novel identified lineage-specific luminal
epithelial progenitor cells in the luminal epithelial cell layer as candidate tumor initiating cells in the prostate cancer mouse model, as indicatedb ya
red background.
doi:10.1371/journal.pone.0005662.g007
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p63 and CK14 expression. QPCR analysis showed a lower CD133
expression in hyperplastic prostates of PSA-Cre;Pten-loxP/loxP mice,
whereas the expression of Sca-1, CD44 and CD117 mRNA was
increased compared to the normal prostate (H. Korsten,
unpublished). These data indicate that the CD49f
+ and the Sca-
1
+CD133
+CD44
+CD117
+ cells are different from the lineage-
specific luminal progenitor cells identified in this study (Figure 7).
Our preliminary findings can form the basis for further isolation
and functional characterization of hyperplastic cells from prostates
of PSA-Cre;Pten-loxP/loxP mice, and of luminal epithelial progenitor
cells from the more distal region of the normal prostate.
The proximal region of the prostate has been proposed as a stem/
progenitor cell niche [28–30]. As shown here, the more compact
Sca-1
+ cells in the luminal epithelial cell layer in the proximal
prostate express many markers of hyperplastic prostate cells and of
progenitors of luminal epithelial cells in the more distal prostate
(Figure5and6).Highexpressionofintegrina2(C D4 9 b)andCD44was
observed in the proximal prostate (H. Korsten, unpublished) [30].
Despite a similar gene expression profile, hyperplasia in Pten
knockout mice did not develop from luminal epithelial cells in the
proximal prostate. In contrast to the distal cells, we did not observe
pAkt overexpression in the proximal cells, suggesting that Pten is
not inactivated in the proximal prostate. At present, it is unknown
whether this is due to low Cre expression or limited susceptibility
of the Pten locus to recombination in this specific part of the
prostate. Alternatively, Pten is inactivated, but PI3K/PTEN
signaling in these cells is not induced. It should be noted that in
PB-Cre;Trp53/Rb knockout mice tumors arise from the proximal
prostate, indicating that proximal cells can function as tumor
initiating cells in cancer models [32].
Recently, fusions between genes encoding ETS transcription
factors and genes encoding prostate-specific genes, mostly
TMPRSS2-ERG, have been reported as most frequent genetic
alteration in early stages of human prostate cancer [58].
Interestingly, Tmprss2 expression is induced late during mouse
prostate development [59]. We also found a fusion between the
KLK2 gene and the ETS gene ETV4 in clinical prostate cancer
[60]. KLK2 is highly homologous to the PSA (KLK3) gene used in
our mouse prostate cancer model for Cre expression. Although it is
unknown in which cell type the gene fusions occur, because of the
high prostate-specificity of most genes that are coupled to ETS
genes it is tempting to speculate that the genetic alterations occur
and/or become manifest in progenitors of luminal epithelial cells
and not in tissue stem cells or multi-potent progenitor cells. These
findings clearly indicate the high importance of identification of
progenitor cells of luminal epithelial cells in the human prostate
and further characterization of the mouse progenitors.
Materials and Methods
Generation of Prostate Targeted Pten Knockout Mice
The generation of PSA-Cre mice (strain FVB), mice carrying the
Pten-loxPallele(strain129Ola), and bi-allelic andmono-allelic prostate
Pten knockout mice have been described previously [13,61]. Mice
were housed according to guidelines of the Erasmus Medical Center,
and procedures were carried out in compliance with standards for use
of laboratory animals. Animal experiments performed in this
manuscript have been approved by the animal experimental
committee of the Erasmus Medical Center (DEC-consult).
RNA extraction, cDNA preparation and QPCR analysis
RNA was isolated from frozen mouse prostates using the
Qiagen RNeasy RNA extraction Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s guidelines, including an on
column DNAseI digestion. RNA quality was checked by agarose
gel electrophoresis. For RNA extraction from normal and
hyperplastic prostates at 2m and 4–5m a pool of prostate lobes
of one mouse was used. Pools of prostates from five mice were used
for each RNA sample from proximal and distal prostate regions of
control littermates (4–5m).
The methods for cDNA preparation and QPCR analysis were
described previously [60]. Primer sequences are given in Table S3.
The expression level of target genes was determined relative to the
endogenous reference Hypoxanthine-guanine Phosphoribosyltransferase
(Hprt).
Immunohistochemistry and Immunofluorescent double
staining
Tissues were fixed in buffered 4% formalin for ,16h at room
temperature, dehydrated, embedded in paraffin and sections were
cut at 4 mm. Antibodies used for immunohistochemistry and
immunofluorescence are listed in Table S4. The Nkx3.1 antibody
was a kind gift from Dr. Cory Abate-Shen. Microwave treatment
was applied for antigen retrieval by boiling in 10 mM sodium
citrate (pH 6.0) for 15 min. For CK19 staining, tissue sections
were pepsine (0.5%) treated for 30 min at 37uC. Primary
antibodies incubation was overnight at 4uC. For immunohisto-
chemistry, tissue sections were incubated with biotin labeled
secondary antibody for 1h at room temperature. Immunoreactiv-
ity was visualized by streptavidin-peroxidase incubation (HK320-
UK, 1:50, BioGenex, San Ramon, CA). For immunofluorescent
pAkt, CK8 and p63 staining, tissue sections were incubated with
FITC/TRITC labeled secondary antibodies (Table S4). The
signals for Clu and Tacstd2 were visualized by incubation with
Rabbit Anti-Goat biotin followed by Streptavidin-TRITC. Anti-
fading fluorescent mounting medium (H-1000, Vector laborato-
ries, Burlingame, CA) containing DAPI (1:2000, Sigma Chemical,
St.Louis, MO) was used to cover the slide. Immunofluorescent
stained slides were analyzed with a DMRXA microscope (Leica,
Wetzlar, Germany).
To estimate the number of progenitor cells in the luminal
epithelial cell layer of normal prostates at 4–5w and at 4–5m, slices
of the mouse anterior lobe were stained for Clu. By counting the
total cell number and the number of Clu
+ cells in a prostate lobe,
an estimation of the frequency of Clu
+ cells could be made.
cDNA microarray hybridization and analysis
The cDNA microarrays were hybridized and normalized as
described previously [62,63]. The common reference, a mixture of
RNAs isolated from mouse adult testis and prostate, was in all
experiments Cy5-labeled. The cDNA microarrays were manufac-
tured at the Central Microarray Facility at the Netherlands
Cancer Institute (NKI, Amsterdam, The Netherlands) and
contained 16,416 spots.
Principal component analysis was performed using the Spotfire
software package (Spotfire, Inc., Sommerville, MA; spotfire
decision site V8.1). For unsupervised hierarchical clustering and
visualization of differentially expressed genes the programs Cluster
and Treeview were used [64]. After setting criteria for unsuper-
vised hierarchical clustering of normal and hyperplastic prostates
(100% signal and at least 2 observations of |0.8|) 528 genes were
selected. Within Treeview, the image contrast and mask value
settings were 1.5 and 0.2 respectively for all figures.
The difference in mean mRNA expression level of a gene was
calculated by substracting the log2 transformed average expression
level in normal prostates from the average expression level in
hyperplastic prostates. Genes were ranked based on gene
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level differences of known genes, which gave a signal in at least two
experiments in one group. In addition, by performing Significance
Analysis of Microarrays (SAM) (Version 1.21) [65] gene expression
levels differences relative to the standard deviation of these
expression levels within one group was calculated. By SAM genes
with an at least 2 fold change in ratio were identified. The q-value
(false discovery rate) for genes identified by SAM analysis was
0.15%.
Microarray data have been submitted to the ArrayExpress
public database (Accession E-MEXP-2029).
Supporting Information
Figure S1 Hyperplastic prostate cells of PSA-Cre;Pten-loxP/
loxP mice have an epithelial progenitor cell phenotype. (A) QPCR
analysis of epithelial cell marker expression in hyperplastic
prostates at 2m and 4–5m. Each group was compased of five
RNA samples. Data are shown as average expression levels +/2
SE relative to Hprt expression. NP: normal prostate, HP:
hyperplastic prostate. (B–I) Immunohistochemical analysis of
epithelial cell markers in the mouse anterior lobe of normal and
hyperplastic prostates at 4–5m. (B) Nkx3.1 NP, (C) Nkx3.1 HP, (D)
CK8 NP, (E) CK8 HP, (F) CK19 NP, (G) CK19 HP, (H) P63 NP
and (I) P63 HP.
Found at: doi:10.1371/journal.pone.0005662.s001 (8.51 MB TIF)
Figure S2 QPCR analysis of the five genes with the lowest
expression in hyperplastic prostates (4–5m). Each group was
composed of five RNA samples. The expression levels in 2m and
4–5m old hyperplastic prostates are shown as average expression
level +/2 SE relative to Hprt expression.
Found at: doi:10.1371/journal.pone.0005662.s002 (6.62 MB TIF)
Figure S3 Number of Clu+ hyperplastic foci in prostates of PSA-
Cre;Pten-loxP/+ mice. At older age (.11m) the number of Clu+
hyperplastic foci increased in prostates of PSA-Cre;Pten-loxP/+
mice. Clu+ hyperplastic foci were counted in fifteen consecutive
slides of a longitudinal embedded anterior prostate lobe. At each
time point the prostates of three mice were analyzed.
Found at: doi:10.1371/journal.pone.0005662.s003 (8.78 MB TIF)
Figure S4 Tacstd2+ cells in the P63+ basal epithelial cell layer of
a normal mouse prostate (4–5w).
Found at: doi:10.1371/journal.pone.0005662.s004 (6.49 MB TIF)
Figure S5 Immunohistochemical analysis of epithelial cell
markers and hyperplastic cell markers in urethra of wild type
mice. (A) CK8, (B) P63, (C) Ppp1r1b, (D) Tacstd2, (E) Clu and (F)
Sca-1.
Found at: doi:10.1371/journal.pone.0005662.s005 (6.95 MB TIF)
Table S1 Full gene names of genes overexpressed in hyperplastic
prostates of PSA-Cre;Pten-loxP/loxP mice.
Found at: doi:10.1371/journal.pone.0005662.s006 (0.03 MB
DOC)
Table S2 Genes with significantly differentially expression in
hyperplastic prostates of PSA-Cre;Pten-loxP/loxP mice as deter-
mined by SAM.
Found at: doi:10.1371/journal.pone.0005662.s007 (0.19 MB
DOC)
Table S3 Primer sequences of genes analyzed by QPCR.
Found at: doi:10.1371/journal.pone.0005662.s008 (0.03 MB
DOC)
Table S4 Information of antibodies used for immunohistochem-
istry and immunofluorescence
Found at: doi:10.1371/journal.pone.0005662.s009 (0.03 MB
DOC)
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